479 INTRODUCTION Growth hormone has been used in the treatment of short stature since 1957 . Prior to 1985, human cadaver-derived pituitary growth hormone was used. Recombinant human growth hormone which was approved in 1985 made available a reliable, virtually unlimited resource to replace human pituitary growth hormone (which was withdrawn due to reported cases of Creutzfeldt-Jakob disease). ...

The spontaneous secretion of growth hormone during a 24 hour period and the response of growth hormone to growth hormone releasing hormone was studied in 13 girls who had received treatment for acute lymphoblastic leukemia that included cranial irradiation with 20-24 Gy in 12-14 fractions. At the time of investigation the girls were at varying stages of puberty and had normal concentrations of ...

levofloxacin is one of the fluroquinoline antibiotic groups, which affect on controlling infections, especially in reproductive organs. it has therapeutic use in numerous countries, but little information exists on the effects of levofloxacin on spermatogenesis when it is used for infectious treatment. the current study was designed to determine whether levofloxacin influences testis tissue and...

This study to evaluate the effect of hormone replacement therapy ( HRT ) and low-dose combinated oral pill on skin thickness , lipid profile and blood chemistry on menopausal woman.This study was carried out in one year randomized prospective study. 36 women were divided into 18 women receiving HRT and the other 18 receiving low-dose oral pill. The result of this study showed an increase in ski...

The goal was to identify the changes in blood levels of hormones, cytokines, and number leukocytes associated with success laser treatment hypertrophic scars. Material Methods — lipid, hormonal, cytokine leukocyte composition studied 15 women normotrophic scars (Group 1) 30 2). Blood taken before on days 5-7 menstrual cycle, followed by treatment. clinical parameters were assessed 3 months afte...

Rising prostate-specific antigen (PSA) in nonmetastatic prostate cancer occurs in two main clinical settings: (1) rising PSA to signal failed initial local therapy and (2) rising PSA in the setting of early hormone-refractory prostate cancer prior to documented clinical metastases. Most urologists and radiation oncologists are very familiar with the initial very common clinical scenario, common...

Endocrine therapy, targeting the oestrogen receptor pathway, is the most common treatment for oestrogen receptor-positive breast cancers. Unfortunately, these tumours frequently develop resistance to endocrine therapies. Among the strategies to treat resistant tumours are sequential treatment (in which second-line drugs are used to gain additional responses) and intermittent treatment (in which...

Markers that predict treatment effect have the potential to improve patient outcomes. For example, the OncotypeDX® RecurrenceScore® has some ability to predict the benefit of adjuvant chemotherapy over and above hormone therapy for the treatment of estrogen-receptor-positive breast cancer, facilitating the provision of chemotherapy to women most likely to benefit from it. Given that the score w...

INTRODUCTION While thyrotropin-releasing hormone is known to be a prolactin-release stimulating factor, thyrotropin-releasing hormone-tartrate and its derivative, taltirelin hydrate, are used for the treatment of spinocerebellar degeneration, a degenerative disease characterized mainly by motor ataxia. We report the case of a patient being treated with a thyrotropin-releasing hormone preparatio...